KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Work In Process (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Work In Process for 13 consecutive years, with $29.4 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 10.14% to $29.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.4 million through Dec 2025, up 10.14% year-over-year, with the annual reading at $29.4 million for FY2025, 10.14% up from the prior year.
  • Work In Process for Q4 2025 was $29.4 million at Supernus Pharmaceuticals, down from $33.4 million in the prior quarter.
  • The five-year high for Work In Process was $46.2 million in Q1 2022, with the low at $9.3 million in Q1 2021.
  • Average Work In Process over 5 years is $28.1 million, with a median of $27.5 million recorded in 2023.
  • The sharpest move saw Work In Process skyrocketed 408.75% in 2021, then crashed 36.0% in 2023.
  • Over 5 years, Work In Process stood at $45.7 million in 2021, then plummeted by 30.63% to $31.7 million in 2022, then fell by 1.57% to $31.2 million in 2023, then fell by 14.38% to $26.7 million in 2024, then rose by 10.14% to $29.4 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $29.4 million, $33.4 million, and $15.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.